Making Financial Headlines · Page 10
Lilly's drug boom gives analysts another target to raise
· New York time
CNBC's Investing Club raised its price target on Eli Lilly as the obesity-drug boom continues. The outlet cited Mounjaro and Zepbound as drivers of the company's momentum and expects more growth. A price target is an assessment, not a guaranteed destination. Still, the revision shows how strongly analysts are weighing demand for Lilly's medicines in their outlook for the company. The forecast gets a larger number, while the actual business must keep doing the work needed to support it. Wall Street can update a target much faster than a drugmaker can deliver another quarter.
Read this story in the full newspaper →Satire. Not factual reporting. Read the original reporting from the linked publishers.